Aspirin in transient ischemic attacks and minor stroke: a meta-analysis

Area of Science:

• Neurology
• Cardiology
• Pharmacology

Background:

• Transient ischemic attacks (TIAs) and minor strokes are critical warning signs for future cerebrovascular events.
• Effective secondary prevention strategies are crucial for reducing morbidity and mortality in affected patients.

Purpose of the Study:

• To evaluate the effectiveness of aspirin, alone and in combination regimens, for secondary prevention in patients with TIAs and minor strokes.
• To synthesize evidence from multiple randomized controlled trials (RCTs) through a meta-analysis.

Main Methods:

• An overview analysis was conducted on seven RCTs involving 6409 patients.
• Patients were categorized into three groups: aspirin alone, aspirin-combination therapy (with sulfinpyrazone or dipyridamole), and placebo.
• Statistical pooling of data was performed to assess treatment efficacy.

Main Results:

• Aspirin monotherapy demonstrated an 18% reduction in the combined outcome of all strokes and cardiovascular deaths.
• Combination regimens, and the overall analysis of aspirin and combination therapies, showed significant risk reductions (odds ratios 0.59-0.78) for total deaths, total strokes, and combined strokes/cardiovascular deaths.
• Modest but suggestive benefits were noted for total cardiovascular mortality.

Conclusions:

• Aspirin is effective in reducing the risk of recurrent strokes and cardiovascular mortality in patients with TIAs and minor strokes.
• Combination therapies involving aspirin may offer enhanced protection, aligning with previous meta-analyses.
• These findings support the use of antiplatelet therapy in secondary stroke prevention.